Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42572   clinical trials with a EudraCT protocol, of which   7010   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000343-14
    Sponsor's Protocol Code Number:AS0007
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-08-31
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2016-000343-14
    A.3Full title of the trial
    Multicenter, Open-Label Study To Assess The Effects Of Certolizumab Pegol On The Reduction Of Anterior Uveitis Flares In Axial Spondyloarthritis Subjects With A History Of Anterior Uveitis (C-VIEW)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects with a documented history of AU
    A.3.2Name or abbreviated title of the trial where available
    C-VIEW
    A.4.1Sponsor's protocol code numberAS0007
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SPRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SPRL.
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointCT Registries & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMannheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name CIMZIA certolizumab pegol 200 mg/ml solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderUCB Pharma S.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCERTOLIZUMAB PEGOL
    D.3.9.1CAS number 428863-50-7
    D.3.9.2Current sponsor codeCDP870
    D.3.9.4EV Substance CodeSUB25423
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Anterior Uveitis (AU) in subjects with Axial Spondyloarthritis (axSpA) and a history of AU.
    E.1.1.1Medical condition in easily understood language
    Anterior Uveitis is an inflammation of the middle layer of the eye. Axial Spondyloarthritis is a chronic inflammatory disease predominantly affecting the axial skeleton (sacroiliac joints
    and spine).
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level SOC
    E.1.2Classification code 10028395
    E.1.2Term Musculoskeletal and connective tissue disorders
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active Axial Spondyloarthritis (axSpA) and a documented history of AU
    E.2.2Secondary objectives of the trial
    - To assess the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active Axial Spondyloarthritis (axSpA) having at least 1 documented history of AU within 12 months prior to Baseline
    - To assess the effect of Certolizumab Pegol (CZP) treatment on axSpA disease activity
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Subjects must have a documented diagnosis of adult-onset axial Spondyloarthritis (axSpA) with at least 3 months’ symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria
    2) Subjects must have active disease at Screening as defined by
    - Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4
    - Spinal pain >= 4 on a 0 to 10 Numerical Rating Scale (NRS; from BASDAI item 2)
    - Nonradiographic (Nr)-axSpA subjects must either have C-reactive protein (CRP) > upper limit of normal (ULN) and /or current evidence of sacroiliitis on magnetic resonance imaging (MRI) (no confirmation by central reading) as defined by ASAS criteria
    - Ankylosing spondylitis (AS) subjects must have evidence of sacroiliitis on x-ray meeting the modified New York (mNY) classification criteria according to the Investigator
    3) Subjects must have a documented history of Anterior Uveitis (AU) diagnosed by an ophthalmologist and have at least 2 AU flares in the past, of which at least 1 AU flare was in the last 12 months prior to Baseline
    E.4Principal exclusion criteria
    - Other inflammatory arthritis
    - Secondary, noninflammatory condition that, in the Investigator’s opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject’s primary diagnosis of axial spondyloarthritis (axSpA)
    - Any history of uveitis except for Anterior Uveitis (AU) associated with axSpA
    - Any condition or complicating factor that may interfere with the AU assessment
    - Retisert® or Iluvien® (glucocorticosteroid implant) within 3 years prior to the Baseline Visit or has had complications related to the device
    - Subject has had Retisert or Iluvien (glucocorticosteroid implant) removed within 90 days prior to the Baseline Visit
    - Intraocular or periocular corticosteroids within 90 days prior to the Baseline visit
    - Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline Visit
    - Cyclophosphamide within 30 days prior to the Baseline Visit
    - Intravitreal methotrexate (MTX) within 90 days prior to the Baseline Visit
    - Intravitreal anti-vascular endothelial growth factor (VEGF) therapy
    E.5 End points
    E.5.1Primary end point(s)
    Number of distinct episodes of anterior uveitis (AU) flares during the Treatment Period
    E.5.1.1Timepoint(s) of evaluation of this end point
    During the Treatment Period up to 96 weeks
    E.5.2Secondary end point(s)
    1. Number of Anterior Uveitis (AU) flares per 100 patient-years in subjects with active axial Spondyloarthritis (axSpA) and a history of AU at Week 48
    2. Number of Anterior Uveitis (AU) flares per 100 patient-years in subjects with active axial
    Spondyloarthritis (axSpA) and a history of AU at Week 96
    3. Number of Anterior Uveitis (AU) flares per 100 patient-years in subjects with active axial
    Spondyloarthritis (axSpA) and at least 1 AU episode within 12 months prior Baseline at Week 48
    4. Number of Anterior Uveitis (AU) flares per 100 patient-years in subjects with active axial
    Spondyloarthritis (axSpA) and at least 1 AU episode within 12 months prior Baseline at Week 96
    5. Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 48
    6. Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 96
    7. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 48
    8. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 96
    9. Percentage of subjects with Axial Spondyloarthritis International Society 20 % response criteria (ASAS20) at Week 48
    10. Percentage of subjects with Axial Spondyloarthritis International Society 20 % response criteria (ASAS20) at Week 96
    11. Percentage of subjects with Axial Spondyloarthritis International Society 40 % response criteria (ASAS40) at Week 48
    12. Percentage of subjects with Axial Spondyloarthritis International Society 40 % response criteria (ASAS40) at Week 96
    13. Percentage of subjects with Axial Spondyloarthritis International Society (ASAS) 5/6 response at Week 48
    14. Percentage of subjects with Axial Spondyloarthritis International Society (ASAS) 5/6 response at Week 96
    15. Percentage of subjects with Axial Spondyloarthritis International Society (ASAS) partial remission (PR) response at Week 48
    16. Percentage of subjects with Axial Spondyloarthritis International Society (ASAS) partial remission (PR) response at Week 96
    17. Change from Baseline in tender joint count (44 joint count) at Week 48
    18. Change from Baseline in tender joint count (44 joint count) at Week 96
    19. Change from Baseline in swollen joint count (44 joint count) at Week 48
    20. Change from Baseline in swollen joint count (44 joint count) at Week 96
    21. Change From Baseline in Physician's Global Assessment of Disease Activity (PhGADA) at Week 48
    22. Change From Baseline in Physician's Global Assessment of Disease Activity (PhGADA) at Week 96
    23. Change From Baseline in Patient's Global Assessment of Disease Activity (PtGADA) at Week 48
    24. Change From Baseline in Patient's Global Assessment of Disease Activity (PtGADA) at Week 96
    25. Change from Baseline in total spinal pain at Week 48 assessed by Numerical Rating Scale (NRS)
    26. Change from Baseline in total spinal pain at Week 96 assessed by Numerical Rating Scale (NRS)
    27. Change from Baseline to Week 48 in the Bath Ankylosing Spondylitis Functional Index (BASFI)
    28. Change from Baseline to Week 96 in the Bath Ankylosing Spondylitis Functional Index (BASFI)
    29. Change from Baseline to Week 48 in Inflammation assessed by the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness and duration
    30. Change from Baseline to Week 96 in Inflammation assessed by the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness and duration
    E.5.2.1Timepoint(s) of evaluation of this end point
    1, 3: During the Treatment Period up to 48 weeks
    2, 4: During the Treatment Period up to 96 weeks
    5, 7, 17, 19, 21, 23, 25, 27, 29: From Baseline to Week 48
    6, 8, 18, 20, 22, 24, 26, 28, 30: From Baseline to Week 96
    9, 11, 13, 15: Week 48
    10, 12, 14, 16: Week 96
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA32
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visit (LSLV)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 86
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 86
    F.4.2.2In the whole clinical trial 86
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    N/A
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-08-31
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-25
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-01-23
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA